JP2021501569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501569A5 JP2021501569A5 JP2020520150A JP2020520150A JP2021501569A5 JP 2021501569 A5 JP2021501569 A5 JP 2021501569A5 JP 2020520150 A JP2020520150 A JP 2020520150A JP 2020520150 A JP2020520150 A JP 2020520150A JP 2021501569 A5 JP2021501569 A5 JP 2021501569A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- measured
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023131574A JP7649825B2 (ja) | 2017-10-10 | 2023-08-10 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
| JP2025035270A JP2025102791A (ja) | 2017-10-10 | 2025-03-06 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195781.4 | 2017-10-10 | ||
| EP17195781.4A EP3470429A1 (en) | 2017-10-10 | 2017-10-10 | Antibodies targeting pdl1 and methods of use thereof |
| EP18167094 | 2018-04-12 | ||
| EP18167094.4 | 2018-04-12 | ||
| EP18180816.3 | 2018-06-29 | ||
| EP18180816 | 2018-06-29 | ||
| PCT/EP2018/077511 WO2019072869A1 (en) | 2017-10-10 | 2018-10-09 | PDL1 TARGETING ANTIBODIES AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131574A Division JP7649825B2 (ja) | 2017-10-10 | 2023-08-10 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501569A JP2021501569A (ja) | 2021-01-21 |
| JP2021501569A5 true JP2021501569A5 (enExample) | 2021-11-11 |
| JP7791650B2 JP7791650B2 (ja) | 2025-12-24 |
Family
ID=63834022
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020520150A Active JP7791650B2 (ja) | 2017-10-10 | 2018-10-09 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
| JP2023131574A Active JP7649825B2 (ja) | 2017-10-10 | 2023-08-10 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
| JP2025035270A Pending JP2025102791A (ja) | 2017-10-10 | 2025-03-06 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023131574A Active JP7649825B2 (ja) | 2017-10-10 | 2023-08-10 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
| JP2025035270A Pending JP2025102791A (ja) | 2017-10-10 | 2025-03-06 | Ｐｄｌ１を標的とする抗体及びそれを用いる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12077588B2 (enExample) |
| EP (1) | EP3694879A1 (enExample) |
| JP (3) | JP7791650B2 (enExample) |
| KR (2) | KR20250057935A (enExample) |
| CN (2) | CN111225926B (enExample) |
| AU (2) | AU2018348430B2 (enExample) |
| CA (1) | CA3074802A1 (enExample) |
| IL (2) | IL273578B1 (enExample) |
| MA (1) | MA50353A (enExample) |
| SG (1) | SG11202001654TA (enExample) |
| WO (1) | WO2019072869A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018280679B2 (en) * | 2017-06-05 | 2025-04-24 | Numab Therapeutics AG | Novel anti-HSA antibodies |
| PE20200849A1 (es) * | 2017-10-10 | 2020-08-20 | Numab Therapeutics AG | Anticuerpo multiespecifico |
| US11208486B2 (en) * | 2019-04-26 | 2021-12-28 | I-Mab Biopharma Us Limited | Human PD-L1 antibodies |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
| WO2024240690A2 (en) * | 2023-05-19 | 2024-11-28 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| WO2025133389A1 (en) | 2023-12-22 | 2025-06-26 | Numab Therapeutics AG | Antibody binding domains having specificity for lilrb2 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| BR0316880A (pt) * | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| EP3763741A1 (en) * | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| US10077312B2 (en) * | 2013-05-10 | 2018-09-18 | Numab Therapeutics AG | CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| IL293435A (en) | 2015-06-15 | 2022-07-01 | Numab Therapeutics AG | Heterodimeric multispecific antibody format |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CN108779176A (zh) | 2016-01-11 | 2018-11-09 | 印希比股份有限公司 | 多价和多特异性41bb结合融合蛋白 |
-
2018
- 2018-10-09 CN CN201880065379.0A patent/CN111225926B/zh active Active
- 2018-10-09 US US16/753,876 patent/US12077588B2/en active Active
- 2018-10-09 KR KR1020257012651A patent/KR20250057935A/ko active Pending
- 2018-10-09 JP JP2020520150A patent/JP7791650B2/ja active Active
- 2018-10-09 AU AU2018348430A patent/AU2018348430B2/en active Active
- 2018-10-09 CN CN202510273782.4A patent/CN120248120A/zh active Pending
- 2018-10-09 CA CA3074802A patent/CA3074802A1/en active Pending
- 2018-10-09 EP EP18785592.9A patent/EP3694879A1/en active Pending
- 2018-10-09 SG SG11202001654TA patent/SG11202001654TA/en unknown
- 2018-10-09 KR KR1020207008775A patent/KR20200063147A/ko not_active Ceased
- 2018-10-09 MA MA050353A patent/MA50353A/fr unknown
- 2018-10-09 WO PCT/EP2018/077511 patent/WO2019072869A1/en not_active Ceased
-
2020
- 2020-03-24 IL IL273578A patent/IL273578B1/en unknown
-
2023
- 2023-08-10 JP JP2023131574A patent/JP7649825B2/ja active Active
-
2024
- 2024-09-02 US US18/822,338 patent/US20250066482A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035270A patent/JP2025102791A/ja active Pending
- 2025-09-21 IL IL323510A patent/IL323510A/en unknown
- 2025-11-28 AU AU2025271488A patent/AU2025271488A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501569A5 (enExample) | ||
| JP2020537520A5 (enExample) | ||
| IL323510A (en) | Antibodies directed against 1PDL and methods of use thereof | |
| JP2021501744A5 (enExample) | ||
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2022177090A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| JP2020124209A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| JP2019500862A5 (enExample) | ||
| JP2016514463A5 (enExample) | ||
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| JP2016519124A5 (enExample) | ||
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| RU2015150149A (ru) | Составы на основе биспецифических антител к il-4/il-13 | |
| JP2013519364A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2014534218A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2011527899A5 (enExample) | ||
| JP2019521647A5 (enExample) | ||
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| JP2015503909A5 (enExample) | ||
| CN106565840B (zh) | 抗乙肝表面抗原的抗体及其用途 |